ProQR Therapeutics (PRQR) EBIT (2013 - 2025)

ProQR Therapeutics (PRQR) has 13 years of EBIT data on file, last reported at -$10.1 million in Q4 2025.

• For the quarter ending Q4 2025, EBIT fell 37.07% year-over-year to -$10.1 million; the trailing twelve-month figure through Dec 2025 stood at -$47.7 million (down 68.34% YoY), and the FY2025 full-year result was -$50.6 million, down 55.31% from the prior year.
• EBIT improved to -$10.1 million in Q4 2025, from -$13.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$3.3 million in Q2 2024 to a low of -$24.5 million in Q3 2022.
• A 5-year average of -$12.3 million and a median of -$10.5 million in 2025 frame the typical range for EBIT.
• Across the five-year window, EBIT plunged 329.6% in 2021 and jumped 75.76% in 2023, its largest moves.
• Tracing PRQR's EBIT over 5 years: stood at -$21.5 million in 2021, then jumped by 74.76% to -$5.4 million in 2022, then plunged by 35.1% to -$7.3 million in 2023, then retreated by 0.78% to -$7.4 million in 2024, then plunged by 37.07% to -$10.1 million in 2025.
• Business Quant data shows PRQR's EBIT at -$10.1 million in Q4 2025, -$13.0 million in Q3 2025, and -$13.8 million in Q2 2025.